Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Other Gross PP&E Adjustments (2019 - 2026)

Myriad Genetics has reported Other Gross PP&E Adjustments over the past 9 years, most recently at $146.9 million for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments fell 11.19% to $146.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $146.9 million through Dec 2025, down 11.19% year-over-year, with the annual reading at $146.9 million for FY2025, 11.19% down from the prior year.
  • Other Gross PP&E Adjustments was $146.9 million for Q4 2025 at Myriad Genetics, up from $144.1 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $233.0 million in Q3 2023 and troughed at $59.5 million in Q2 2021.
  • The 5-year median for Other Gross PP&E Adjustments is $144.1 million (2025), against an average of $134.0 million.
  • Year-over-year, Other Gross PP&E Adjustments skyrocketed 390.12% in 2021 and then dropped 24.76% in 2024.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $64.1 million in 2021, then skyrocketed by 32.76% to $85.1 million in 2022, then soared by 102.47% to $172.3 million in 2023, then decreased by 4.0% to $165.4 million in 2024, then fell by 11.19% to $146.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Other Gross PP&E Adjustments are $146.9 million (Q4 2025), $144.1 million (Q3 2025), and $141.2 million (Q2 2025).